PARP1 and neoplasm: Jamal K, Galbiati A, Armenia J, Illuzzi G, Hall J, Bentouati S, et al. Drug-gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP Inhibition.